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ABSORPTION OF IODOCHLORHYDROXYQUIN IN HUMANS 
To t he Editor: 
The article by S. J. Sto hs et a l (Februa ry 1984 ) studying the percu-
taneous absorpt ion of iodochlorhydroxyquin in humans is completely 
at variance with previously published work on this topic. Fischer and 
Hart vig [lj , Fischer et a l [2). and Degen et al [3] have all looked at. the 
percuta neous absorption of this drug, eit her on its own or in combina-
tion with a corticosteroid. Although other facto rs in the study designs 
have varied, e.g., hea lthy or diseased volunteers, quantity of drug 
applied, body a rea being treated, the most signi ficant different factor 
would appear to be the method of calculating the a mount absorbed. 
Stohs et al conclude that 40% of t he applied dose was absorbed based 
on the quanti ty of drug remaining on the forearm 12 h a fte r app lication. 
The other th ree workers calculated the amount absorbed from urinary 
excretion data a lone, and concluded that the amount absorbed was 1.2-
4.5 %. 
[ am amazed that Stohs et al did not comment on t his 10-fold 
difference, particularly in relation to the difficul t ies inherent in t he 
method they used for s tudying percutaneous absorpt ion [4]. 
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REPLY 
The key to the question raised by Mr. Wilcock is embodied in his 
statement "the other t hree workers ca lculated the amount absorbed 
from urina ry excretion data alone." We have recent ly completed a 
study (J Pharm Sci, in press) where we have examined percutaneous 
absorption and disposition of iodochlorhydroxyquin in dogs. Based on 
urinary excretion data alone, approximately 3% of the administered 
dose of t he drug was excreted in the urine, agreeing with the resul ts of 
other investigators. However, we have also analyzed fecal excretion a nd 
found that approximately 10 times as much of the drug is excreted in 
the feces as in t he urine. Thus, the feces and not the urine is t he 
primary route of excretion of this drug. Bas ing absorption on urinary 
data can lead to erroneous results, particula rly when other major routes 
of excretion are involved. In t he studies involving dogs, over 50% of 
the topically applied drug was absorbed in 16 h, agreeing well with our 
report of approximately 40% absorption in humans in 12 h. 
Wilcock has suggested t hat enhanced difficulties exist in t he method 
which we used for studying percuta neous absorption. Measuring the 
amount of drug applied a nd t he a moun t of drug remaining afte r a 
prescribed period of t ime provides a straightforward and reproducible 
method of determining percutaneous abso rption. In fact, this is the 
most direct method for determining absorption, and avoids the pitfa lls 
associated with multiple routes of excretion. 
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